
|Articles|June 15, 2004
Short-term results of custom ablation stable over 2 years
Higher-order aberrations decreased in most patients, with the change from baseline reaching up to 50%.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Nanoscope secures new US patent for Multi-Characteristic Opsin (MCO) technology platform
2
Glaucoma innovation: Eight themes to watch in 2026
3
Ollin Biosciences reports positive head-to-head phase 1b data for OLN324 vs faricimab
4
First patient treated in dose-expansion portion of SpliceBio's phase 1/2 ASTRA clinical trial
5












































